11 completed, 2 terminated, 1 not yet recruiting, 1 unknown. 15 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 11, Terminated 2, Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Blepharitis: new trials by email Literature Review of Blepharitis trials Research Report on Blepharitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis APT-001 topical ophthalmic ointment (spinosad), Placebo control for APT-001 topical ophthalmic ointment - Blepharitis | Phase 2 | Not yet recruiting | Aperta Biosciences, LLC | 15 | 2026-12-01 | 2026-11-12 |
| A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis. APT-001 topical ophthalmic ointment (spinosad), Vehicle control for APT-001 topical ophthalmic ointment - Blepharitis | Phase 2 | Completed | Aperta Biosciences, LLC | 66 | 2025-11-01 | 2026-10-27 |
| Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex Vehicle of TP-03 - Meibomian Gland Dysfunction, Demodex Infestation of Eyelid | Phase 2 | Unknown | Tarsus Pharmaceuticals, Inc. | 36 | 2023-08-01 | 2024-04-09 |
| Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD TP-03, TP-03 Vehicle - Meibomian Gland Dysfunction, Blepharitis | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 39 | 2022-08-03 | 2025-10-01 |
| Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis NCX 4251, Placebo - Blepharitis | Phase 2 | Completed | Nicox Ophthalmics, Inc. | 224 | 2020-12-14 | 2023-06-18 |
| Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis TP-03, 0.25%, TP-03 Vehicle - Blepharitis | Phase 2 / Phase 3 | Completed | Tarsus Pharmaceuticals, Inc. | 421 | 2020-09-09 | 2023-12-21 |
| Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Fluticasone Propionate, Placebo - Blepharitis | Phase 2 | Completed | Nicox Ophthalmics, Inc. | 36 | 2019-03-18 | 2023-06-18 |
| Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease KPI-121, Vehicle - Blepharitis | Phase 2 | Completed | Kala Pharmaceuticals, Inc. | 206 | 2014-07-01 | 2021-01-11 |
| A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636) Azithromycin ophthalmic solution, 1%, Vehicle - Blepharitis | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 40 | 2010-12-01 | 2013-11-21 |
| Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis Azithromycin, Povidone - Blepharitis | Phase 2 | Completed | Laboratoires Thea | 93 | 2010-03-01 | 2014-11-04 |
| The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Azithromycin ophthalmic solution, 1%, Placebo - Blepharitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 314 | 2009-05-01 | 2013-11-21 |
| The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period Azithromycin ophthalmic solution, 1%, Placebo - Blepharitis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 313 | 2009-04-01 | 2011-09-26 |
| Tea Tree Oil in the Treatment of Chronic Blepharitis Tea Tree Oil - Blepharitis | Phase 2 | Completed | Federal University of São Paulo | 34 | 2009-04-01 | 2010-02-23 |
| A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates Moxifloxacin/dexamethasone phosphate ophthalmic solution, Moxifloxacin ophthalmic solution 0.5%, Dexamethasone phosphate solution, 0.1% - Corneal Infiltrates | Phase 2 | Terminated | Alcon Research | 144 | 2007-12-01 | 2012-12-05 |
| Treatment of Patients With Blepharitis and Facial Rosacea COL-101 (doxycycline, USP) capsules, placebo - Blepharitis, Meibomianitis | Phase 2 | Completed | Galderma R&D | 70 | 2007-11-01 | 2021-02-18 |
Meibomian Gland Dysfunction (3) · Corneal Diseases (1) · Dry Eye Syndromes (1) · Inflammation (1) · Meibomitis (1) · Pain (1)
Eye Diseases (15) · Eyelid Diseases (15) · Pathological Conditions, Signs and Symptoms (2) · Lacrimal Apparatus Diseases (1) · Neurologic Manifestations (1) · Pathologic Processes (1) · Signs and Symptoms (1)
spinosad (2) · Azithromycin (1) · Capsules (1) · Doxycycline (1) · Fluticasone (1) · Loteprednol Etabonate (1) · Moxifloxacin (1) · Povidone (1) · Tea Tree Oil (1)
Merck Sharp & Dohme LLC (3) · Tarsus Pharmaceuticals, Inc. (3) · Aperta Biosciences, LLC (2) · Nicox Ophthalmics, Inc. (2) · Alcon Research (1) · Federal University of São Paulo (1) · Galderma R&D (1) · Kala Pharmaceuticals, Inc. (1) · Laboratoires Thea (1)
United States (10) · Guatemala (2) · Brazil (1) · France (1)
Josue Moran, Ph.D. (2) · Nicox Ophthalmics (2) · Charles Johnson, MBChB (1) · Damien Goldberg, MD (1) · David Wirta, MD (1) · Jodi Luchs, MD (1) · John Sheppard, MD (1) · Joseph Tauber, MD (1) · Kelly Nichols, OD, PhD (1) · Kenneth Sall, MD (1) · Marc Abrams, MD (1) · Michael Graeber, MD (1) · Mitchell C Shultz, MD (1) · Mitchell Shultz, MD (1)
2009 (1)